Skip to main navigation
Skip to content

Top Bar

  • info@eledon.com
  • +1 949.238.8090

Main navigation

  • Home
  • About Us
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Governance
  • R&D
    • R&D Overview
    • CD40L Pathway
    • Pipeline
    • AT-1501
    • Phase 1 KLH Challenge
  • Investors
    • News
    • Events
    • Presentations
    • Stock Information
    • SEC Filings
    • Governance
    • Investor FAQs
    • Contact
  • Join the team
  • Contact Us

Investors

Investor Relations

  • Investors
  • News
  • Events
  • Presentations
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Investor FAQs
  • Contact Investor Relations

News


Date Title
04/13/2016 Summary ToggleTokai Announces Presentations on Galeterone at the AACR Annual Meeting 2016
04/06/2016 Summary ToggleTokai Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
03/30/2016 Summary ToggleTokai Announces Dosing of First Patient in Phase 2 Expansion Study of Galeterone in Enzalutamide-Refractory mCRPC Patients
03/21/2016 Summary ToggleTokai Strengthens Development Team Through the Addition of Kelly Lindert, M.D., as Executive Vice President and Head of Development
03/10/2016 Summary ToggleTokai Pharmaceuticals Reports Full Year 2015 Financial Results
03/10/2016 Summary ToggleOticPharma to Present at the 28th Annual ROTH Conference
02/22/2016 Summary ToggleOticPharma to Present at the 2016 BIO CEO & Investor Conference
01/08/2016 Summary ToggleTokai Announces Presentation of New Data Highlighting Unique Galeterone Mechanism at ASCO Genitourinary Cancers Symposium
01/07/2016 Summary ToggleTokai Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
Displaying 61 - 69 of 69 results

Toolkit

Print Page Email Alerts RSS Feeds Contact

Footer

Quick links

  • Home
  • About Us
  • CD40L Pathway
  • Pipeline
  • AT-1501
  • KLH Challenge
  • Contact Us

Footer Investor Links

 

  • Investors
  • Press Releases
  • Governance
  • Stock Information
  • SEC Filings
  • Investor Email List
© 2021 Eledon Pharmaceuticals, Inc. - All Rights Reserved.